Allorion Therapeutics inks $40m Series A

Allorion Therapeutics, a company focusing on next-generation precision medicine for oncology and autoimmune disease, has secured $40 million in Series A financing.

ByIris Dorbian

24 November 2021•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Deals Healthcare Briefs

Allorion Therapeutics inks $40m Series A

IDG Capital

Med-Fine Capital

Octagon Capital

Qiming Venture Partners

TF Capital

Related articles